Home/Pipeline/NA-841

NA-841

Huntington's Disease

Phase 2AActive

Key Facts

Indication

Huntington's Disease

Phase

Phase 2A

Status

Active

Company

Biomed

About Biomed

Biomed Industries is a late-stage private biotech with a broad and advanced pipeline targeting major neurodegenerative, metabolic, and cardiovascular diseases. Its core strategy is underpinned by a proprietary 'Unified Acceleration Platform,' a theoretical and AI-driven framework positing shared biological dysfunctions across these disease areas. The company has multiple Phase 2 and Phase 3 assets, most notably NA-931 for obesity and NA-831 for Alzheimer's, and one FDA-approved device, the MICROS Infusion System.

View full company profile

Therapeutic Areas

Neurological Diseases Metabolic Disorders Cardiovascular Diseases Rare Diseases

Other Huntington's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
Huntington's Disease Program	Rumi Scientific	Pre-clinical	Active
SOM3355	SOM Biotech	Phase 3	Active
LETI-101	ElevateBio	Preclinical	Active
Somatic Expansion Inhibitor Program	LoQus23 Therapeutics	Preclinical	Active
Preclinical Program	Excision BioTherapeutics	Preclinical	Active
T3D-959 (Future)	T3D Therapeutics	Pre-clinical / Research	Active
HD mAb Therapy	HD Immune	Pre-clinical	Active
TT-P34	Teitur Trophics	Pre-clinical	Active
INT41	Vybion	Pre-clinical	Active
Huntington's Program	reMYND	Pre-clinical	Active
Pridopidine	Prilenia Therapeutics	Phase 3	Active